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Comparative levels of tissue enzymes concerned in the early
metabolism of 5-fluorouracil in normal and malignant
human colorectal tissue
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University Department ofSurgery, St. James's University Hospital, Leeds, LS9 7TF, UK.
Since its introduction nearly 30 years ago, 5-
Fluorouracil (5-FU) has been used extensively both
as a single agent and in combination therapy in the
treatment of advanced colorectal malignancy
(Gilbert, 1982 and Davis, 1982). This accumulation
of experience has revealed a clinical response rate
which remains stubbornly in the region of 20-25%.
Clearly pre-selection of those patients that might
benefit from treatment would be advantageous both
in terms of an aggressive policy towards the likely
"responders" and the avoidance of unnecessary
chemotherapy to the majority of patients.
Unfortunately, previous studies have not revealed
clinical features that might predict the response to
5-FU leading some workers to investigate the
biochemical characteristics of individual tumours;
in particular the enzymes considered responsible for
the metabolism of the drug (Moran & Heidelberger,
1979).
In its original form 5-FU is inactive and, in order
to exert its cytotoxic effect, has to be converted to
one of its active nucleotides down one of several
metabolic pathways. In the first of these, long
considered the most important 5-FU is converted to
5-fluorodeoxyuridine 5'-monophosphate (FdUMP).
This nucleotide is a potent inhibitor of thymidylate
synthetase and, by interfering with the supply of
thymidine triphosphate, affects the synthesis of
DNA. More recently it has been suggested that not
all the cytotoxic action of 5-FU can be explained in
this way and that a further important effect is
incorporation of 5-FU into RNA (Heidelberger et
al., 1983). Such an action requires conversion of 5-
FU to 5-fluorouridine 5'-monophosphate (FUMP)
either directly using the enzyme phosphoribosyl
transferase (PRT) or indirectly via 5-fluorouridine,
using the enzymes uridine phosphorylase (UP) and
uridine kinase (UK).
There is, as yet, little data on the levels of these
three enzymes in human colorectal epithelium. For
this reason and because of their obvious importance
in the initial steps of metabolism of 5-FU this study
was designed to measure the levels of enzymes in a
series of matched normal and malignant specimens
of human colorectal tissue.
Twenty-eight patients presenting with primary
malignant lesions of the colorectum were studied
(males= 17, females =1 with a mean age of 67.3
range 51-82). Details of the site, stage and grade of
individual tumours are contained in Table I.
Table I Clinical details of 28 colonic
tumours studied
A. Site Right Colon = 7
Left Colon = 9
Rectum = 12
B. Stage Dukes' A = 0
B =13
C =10
Distant metaseses - 5
C. Grade Well 12
Moderate 12
Poor 3
Unclassified 1
At the time of surgery samples of both normal
and malignant colonic epithelium were taken from
the freshly-excised specimens, snap frozen in liquid
nitrogen and stored at -70°C. Tissue extracts were
obtained by homogenising the specimens in an
equal volume of ice-cold lOmM tris/HCl buffer
(pH 7.5), containing 10mM mercaptoethanol,
centrifuging at 100,000g for 30min at 4°C and
collecting the supernatant to store at -70°C. All
reagents except where otherwise stated were of
analytical grade from BDH Chemicals Ltd. (Poole).
The assay of phosphoribosyl transferase (PRT)
(EC 2.4.2.9) was adapted from the radioisotopic
method described by Reyes (1969). Sixty ,ul of
extract (1OmM tris/HCl, pH7.5) was incubated at
37°C for 30min with 20u1 of 6.0mM [6-3H] 5-FU
(Amersham), 2041 of 400mM tris/HCl (pH9.8) and
40,p1 of 15.0mM 5-phosphoribosyl-1-pyrophosphate
in 15mM MgCl2. Twenty M1 aliquots were taken at
0, 10, 20 and 30min and mixed with 500MI 750mM
ammonium acetate (pH9.0). The amount of
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[6-3H]FUMP formed was measured by applying
the mixture to a boronate affinity gel prepared as
described by Uziel et al. (1976). The gel was eluted
with 250mM ammonium acetate (pH8.8) to remove
unconverted [6-3H] 5FU and then with 100mM
formic acid to remove the [6-3H] FUMP. The
latter was counted using a Phillips PW 4540 liquid
scintillation analyser and the specific activity of the
PRT expressed as nmol [6-3H] 5FUMP produced
h- g- 1 protein. The protein content of the
supernatant was determined using the Biuret
method.
The assay of uridine kinase (UK) - (E.C. 2.7.1.48)
was based on the radio-isotopic method described
by Ahmed et al. (1981). Forty yl of extract in
10mM tris HCI, pH7.5 (600-900pg protein) was
incubated for 40min at 37°C with 40p1 of 50mM
[5,6-3H] uridine (Amersham), 40pl of 69.5mM
ATP, 40pl of 62.5mM MgCl2 and 40pl of M
tris/HCl (pH 7.5) containing 50mM fl-mercapto-
ethanol. TwentyM1 aliquots were taken at 2, 10, 20, 30
and 40min and spotted on DE-81 discs (Whatman,
Biochemical Ltd.). Unconverted [5,6-3H] uridine
was eluted from the discs with a continuous stream
of water. [5, 6-3H] uridine monophosphate (UMP)
was eluted from the disc in 1 ml of 0.1 M HCl/0.5 M
NaCl into scintillation vials and counted in a liquid
scintillation analyser (Phillips PW 4540). The
specific activity of UK was expressed as nmols of
[5,6-3H] UMP h-' g-1 protein in extract.
Uridine phosphorylase (UP) - (EC 2.4.2.3)
measurements were based on the
spectrophotometric method described by Yamada et
al. (1978). Extract (50MI) in 10mM tris/HCl (pH7.5)
was incubated at 37°C for 15min with 1.35ml of
l11mM Na2HPO4/KH2PO4 and 0.1ml of 50mM
uridine. The reaction was stopped by the addition
of 75pI of perchloric acid. Control tubes had the
uridine added after the perchloric acid. After
centrifugation at 15,000g for 10min and adjustment
of the pH to 10 with 5 M NaOH, the absorbance of
UV light at 290mM was measured. Protein
concentration of the supernatant was determined
using the Biuret method and the activity of the
enzyme was expressed in mmol of uracil h-1g-1
protein in extract.
The values for the three enzymes PRT, UP and
UK in matched normal and malignant tissue are
shown in Figure la-c respectively, with the median
values and interquartile range in Table II.
There is a wide range of values for PRT in
normal colonic tissue, however, it is evident that the
corresponding values in the matched malignant
tissue are elevated as compared with the normal
epithelium. There appears to be no correlation
between the level of the enzyme and the site, stage
or grade of tumour as demonstrated in Figure 2a-c.
The difference between values of PRT in normal
Table II The median values and interquartile ranges of 3
enzyme levels in normal and tumour tissue
PRT UP UK
(nmolh- g-1) (mmolh- g-1) (nmolh- g-1)
(n=22) (n=12) (n=18)
Normal 9.84 12.98 2.00
(7.29-11.69) (9.33-26.91) (1.72-2.74)
Tumour 19.02 30.53 3.32
(13.80-25.65) (24.74-51.25) (2.28-4.59)
and malignant tissue are highly significant using the
Wilcoxon signed rank test for non-parametric data
(P<0.005).
A similar pattern is observed for values of UP
although this is based on a smaller sample size
(n= 12). Again, with three exceptions, the values
obtained for malignant tissue are significantly
higher than for the corresponding normal tissue
(P<0.005). There appears to be no relationship
between the level of enzyme and site, stage or grade
of tumour.
Finally, the values for the enzyme uridine kinase
(UK) are shown in Figure lc. Although many
tumours exhibit the pattern previously seen with
PRT and UP there are several cases where the
levels in normal and malignant tissue are either
equivalent or even reduced in the tumour. The
significance of this is not readily apparent when one
studies the tumours in question.
Although there appeared to be a linear
relationship between levels of PRT and UK (r=0.75,
P<0.001) in 18 cases where both enzymes were
assayed on the same tissue no other correlation
could be found, either between PRT and UP or UP
and UK.
Despite the controversy that continues to
surround the mechanism of cytotoxicity of 5-FU,
be it inhibition of DNA synthesis or a direct effect
on the maturation of RNA (Heidelberger et al.,
1983), it is clear that to have any effect 5-FU must
be converted to one of two active nucleotides,
FdUMP or FUMP. It is evident therefore that the
enzymes responsible for these reactions should be
studied in human material in an attempt to explain
the relative resistance to 5-FU seen in 75-80% of
colorectal malignancies.
Studies on cultured cells which have been selected
for their resistance to 5-FU have shown decreased
levels of the enzyme PRT. Similarly decreased levels
of UK have been detected in cells which are
resistant to fluorouridine (Heidelberger et al., 1983).
There are little data at the present time on these
anabolic enzymes in human colorectal tissue. Weber
(1980) studying 9 cases of primary colorectal
carcinoma, showed an increase in PRT levels in
malignant versus normal tissue. This increase was of5-FU METABOLIZING ENZYMES IN COLORECTAL CANCER 713
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Figure la-c Values for the three enzymes (a) phosphoribosyl transferase, (b) uridine phosphorylase and (c)
uridine kinase in matched normal and malignant tissue.
the same order of magnitude as this present series
(i.e. x 2). Nahas et al., 1974 studied 100
individual matched pairs of tissue and, although
suggesting that a higher ratio of tumour PRT to
normal PRT favoured a positive clinical response, it
was not possible to relate enzyme values in
individual patients to clinical response. We similarly
have found a wide range of values for PRT both in
normal and malignant tissue. Although the levels
are in general elevated in the latter we have no
information on the sensitivity of these individual
tumours to 5-FU treatment.
Previous studies have shown that levels of UK
are also elevated in malignant colorectal tissue
(Weber, 1982) although the actual level may vary
enormously (Otal-Brun & Webb, 1979 and Ahmed
et al., 1982). It is interesting to note that in 7 of our
cases the level of UK in tumour tissue was either
equivalent or less than the corresponding normal
tissue. As with the results for PRT we were unable
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to relate this to any obvious clinical parameter
either in the patient or the type, stage or grade of
tumour.
Unlike Weber et al. (1980), we have shown a
similar pattern with UP as with PRT i.e. an overall
increase in the tumour UP levels as compared with
the corresponding normal tissue. Although based
on a smaller series of patients (n= 12), the
differences were significant (P<0.005 Wilcoxon's
signed rank test).
This study has demonstrated not only that the
three enzymes responsible for conversion of 5-FU
to 5-FUMP are present in malignant colorectal
tissue but that in many cases the levels are
increased over those found in corresponding paired
non-malignant epithelium. It seems unlikely,
therefore, that the diappointing clinical response to
5-FU in the majority of patients with colorectal
malignancies is due to a deficiency in one of these
vital anabolic enzymes. However, prior to
investigating other parts of the metabolic pathway
further work is needed, both on the specific kinetic
constants of the enzymes and on the levels of
substrates present in normal and malignant cells.
This work was supported by a grant from the Yorkshire
Cancer Research Campaign.
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